Non-Alcoholic Fatty Liver Disease
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Non-Alcoholic Fatty Liver Disease

What is the definition of Non-Alcoholic Fatty Liver Disease?

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition that is characterized by a buildup of fat in the liver, which can lead to liver damage. The liver is part of the digestive system, and it helps break down food, store energy, and remove waste products. If more than 5 percent of the liver contains fat, the liver is considered to be fatty (steatotic).

What are the causes of Non-Alcoholic Fatty Liver Disease?

The specific causes of MASLD are unclear, although this condition is likely a result of both environmental factors and changes in several genes. Genetic changes that increase the risk of disease are called pathogenic variants.

What are the different types of Non-Alcoholic Fatty Liver Disease?

Common conditions include: Nonalcoholic Steatohepatitis (NASH)

How prevalent is Non-Alcoholic Fatty Liver Disease?

MASLD occurs in about 25 percent adults and 7 to 14 percent of children worldwide. It is the most common chronic liver disorder in Western countries, including the United States, and its prevalence is increasing along with the rising prevalence of obesity. It is estimated that MASLD will affect over half of individuals by 2040.

Is Non-Alcoholic Fatty Liver Disease an inherited disorder?

An increased risk of developing MASLD can be passed down through generations in families, but the inheritance pattern is unknown.

Who are the top Non-Alcoholic Fatty Liver Disease Local Doctors?
Karn Wijarnpreecha
Elite in Non-Alcoholic Fatty Liver Disease
Hepatology | Transplant Surgery
Elite in Non-Alcoholic Fatty Liver Disease
Hepatology | Transplant Surgery

Banner - University Medicine Transplant Institute

1441 North 12th Street, Floor 2, 
Phoenix, AZ 
Languages Spoken:
English, Thai
Accepting New Patients
Offers Telehealth

I love running, traveling to the new places, and watching sports. Dr. Wijarnpreecha is rated as an Elite provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. His top areas of expertise are Non-Alcoholic Fatty Liver Disease, Cirrhosis, Malabsorption, Liver Transplant, and Kidney Transplant.

Srinivasan Dasarathy
Elite in Non-Alcoholic Fatty Liver Disease
Transplant Surgery
Elite in Non-Alcoholic Fatty Liver Disease
Transplant Surgery

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
Languages Spoken:
English, Hindi

Srinivasan Dasarathy is a Transplant Surgeon in Cleveland, Ohio. Dr. Dasarathy is rated as an Elite provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. His top areas of expertise are Non-Alcoholic Fatty Liver Disease, Liver Failure, Nonalcoholic Steatohepatitis (NASH), Liver Transplant, and Endoscopy.

 
 
 
 
Learn about our expert tiers
Learn More
Sanjaya K. Satapathy
Elite in Non-Alcoholic Fatty Liver Disease
Transplant Surgery | Hepatology
Elite in Non-Alcoholic Fatty Liver Disease
Transplant Surgery | Hepatology

Northwell Health Physician Partners Sandra Atlas Bass Center For Liver Diseases

400 Community Drive, 1st Floor, 
Manhasset, NY 
Languages Spoken:
English, Hindi
Offers Telehealth

Dr. Sanjaya K. Satapathy is the medical director of the Center for Liver Disease and Transplantation at the Northwell Transplant Institute, program director of Northwell's Transplant Hepatology Fellowship, and professor of medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.His path to medicine began in India, where he was inspired by his father an engineer with a passion for homeopathy to pursue a career in healthcare. He earned his medical degree from Veer Surendra Sai Medical College, followed by fellowship training in gastroenterology and hepatology in the early 2000s. During that time, he witnessed the profound need for liver transplantation in India, where access remained scarce.While presenting his research at a conference in the United States, Dr. Satapathy was drawn to the opportunities and possibilities for advancing transplantation in America. He decided to continue his career in the United States, completing additional residency and fellowship training before serving as a transplant hepatologist in Memphis. In 2019, he was recruited to Northwell.It was a dream to begin from zero and build a transplant program that could be a model not just for the area or the state, but for the country, says Dr. Satapathy. Within only a few years, we've been able to achieve that goal, because Northwell has all the elements and resources to be one of the best programs in the nation. The expertise we have is unparalleled, with a collaborative team that encompasses all levels of care.The program was founded just in time for a huge surge in demand for liver transplants in the area, he adds. Liver disease and other liver issues are on the rise, making the need for an extensive program crucial for those in the New York region. Part of the program's strength is innovation. For example, Northwell is utilizing an approach that allows donated organs to be safely preserved for a longer period of time, which means needed organs can travel longer distances even from as far away as Hawaii. Northwell is also running several clinical trials on transplant medications and operates a robust transplant hepatology fellowship program to train the next generation of doctors a program Dr. Satapathy launched.I'm passionate about this work, and particularly about my patients, he says. I see every patient as my family, and my focus is on what I can do next to help them. Dr. Satapathy is rated as an Elite provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. His top areas of expertise are Spontaneous Bacterial Peritonitis, Non-Alcoholic Fatty Liver Disease, Hepatitis, Liver Transplant, and Endoscopy.

What are the latest Non-Alcoholic Fatty Liver Disease Clinical Trials?
Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases.

Summary: Development of preclinical translational models for chronic liver tumors and diseases study, such as spheroids cultured in autologous medium and murine xenograft models to test the efficacy of new therapeutic strategies.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Who are the sources who wrote this article ?

Published Date: April 01, 2026
Published By: National Institutes of Health